Abstract | BACKGROUND: METHODS: RESULTS: Of the 138 randomized patients, 135 received at least 1 dose of study medication (70 patients, basiliximab; 65 patients, ATG). Demographic characteristics were similar between the basiliximab and ATG-treatment groups. At 12 months, the rate of biopsy-proven acute rejection was 19% and 20%, respectively, in the basiliximab and ATG groups. Although the overall profile of adverse events was similar between basiliximab- and ATG-treated patients, adverse events considered by the investigators to be associated with the study drug occurred more often among patients receiving ATG (42% vs. 11% with basiliximab). CONCLUSIONS:
|
Authors | H Sollinger, B Kaplan, M D Pescovitz, B Philosophe, A Roza, K Brayman, K Somberg |
Journal | Transplantation
(Transplantation)
Vol. 72
Issue 12
Pg. 1915-9
(Dec 27 2001)
ISSN: 0041-1337 [Print] United States |
PMID | 11773888
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antilymphocyte Serum
- Immunosuppressive Agents
- Recombinant Fusion Proteins
- Basiliximab
|
Topics |
- Acute Disease
- Adult
- Aged
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antilymphocyte Serum
(adverse effects, therapeutic use)
- Basiliximab
- Female
- Graft Rejection
(prevention & control)
- Graft Survival
- Humans
- Immunosuppressive Agents
(adverse effects, therapeutic use)
- Kidney Transplantation
- Male
- Middle Aged
- Recombinant Fusion Proteins
- Survival Analysis
- Transplantation, Homologous
|